Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Slides:

Advertisements

Similar presentations

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Advertisements

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Nonmyeloablative conditioning for relapsed follicular lymphoma

Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease by Caterina P. Minniti, Caroline Cantilena,

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Genetic sequence analysis of inherited bleeding diseases

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Protease inhibitors potentiate chemotherapy-induced neutropenia

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

by Alexander Röth, Andreas Hüttmann, Russell P

by Ernest Beutler Blood Volume 98(9): November 1, 2001

An actuarial GPS for hemophilic longevity

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Symptomatic venous thromboembolism after femoral vein harvest

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Annexin and APS: the clot thickens

by John J. Strouse, Megan E. Reller, David G

Caitlin W. Hicks, MD, MS, Natalia O. Glebova, MD, PhD, Kristen M

Chronic graft-versus-host disease

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Overall survival by SCT versus observation in first complete remission

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Volume 2(Supplement 1):46-49

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

Influence of ASGR2 expression on survival.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi Sidana, Alok A. Khorana, and Keith R. McCrae Blood Volume 122(21):3626-3626 November 15, 2013 ©2013 by American Society of Hematology

Survival curves depicting survival (in months) for patients without venous thromboembolic disease (VTE), symptomatic VTE and incidental VTE. Patients with VTE, both incidental and symptomatic, had significantly worse survival than those without (p<0.001). Survival curves depicting survival (in months) for patients without venous thromboembolic disease (VTE), symptomatic VTE and incidental VTE. Patients with VTE, both incidental and symptomatic, had significantly worse survival than those without (p<0.001). There was no significant difference in survival between patients with symptomatic and incidental VTE (p=0.674). Surbhi Sidana et al. Blood 2013;122:3626 ©2013 by American Society of Hematology